FLT3 and kidney cancer: Also FLT3 [35], a gene that is upregulated in our case is inhibited by Sorafenib a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma) FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.